Action steps for African Business Schools
2011-05-24 13:56:36 UTC
Case Study: Gilead Sciences: the Gilead access program for HIV drugs
Title
Gilead Sciences: the Gilead access program for HIV drugs
Author
Baron, D; Krehiel, K: Tayan, B
Pages
10
Product Type
Reference #
P53A
Teaching Note
Institute
Setting
Africa
Year
2007
Keywords
AIDS; Developing countries; Government policy; Public policy; Public relations; Strategy formulation
Summary/
Abstract
Abstract
Describes the initial considerations of Gilead Sciences as it designed a strategy for delivering its AIDS drug Viread to developing nations in Africa. In October 2001, Gilead Sciences received approval from the US Food and Drug Administration for the commercial sale of Viread, a significant new drug for the treatment of HIV / AIDS. Viread proved to be an immediate success, increasing rapidly in sales and market share in the United States within its first year on the market. As Gilead made plans to take the drug global in early 2003, a high priority was to make the drug readily available to millions of people in the least developed nations, where the HIV virus was having its most devastating effects. Pricing and distribution were key considerations. Gilead did not have a distribution system in place in any of these countries, and the price charged in the United States would be prohibitive in the developing
The Impact of AABS Video
"The impact of AABS Video" was filmed at the Gordon Institute of Business Science, Johannesburg and at the University of Cape Town Graduate School of Business, Cape Town during the AABS Members Meeting and Conference 2011.
- Find out more about becoming an AABS Member or an AABS Pipeline School
- Interested in consulting to our member schools or teaching on our AABS programmes? contact us.
AABS is proud to announce our new project: African Agribusines Network (AAgri.net). Visit the website.
Reports on the AABS Members Meeting 2011 and Responsible Management in Africa Conference 2011
